26 Apr 2026
The Wegovy Pill in Ireland: EU Approved, But When Will You Actually Get It?
All medical information is reviewed by our clinical partners at MedicOnline.
Dr. Jahan Khan, CMO @ MedicOnline
IMC 409788
The Wegovy pill is a daily pill that delivers the same weight loss as a weekly injection, with no needles and no fuss. When we first published this guide in April 2026, the Wegovy pill was still working its way through European regulation. Since then, things have moved quickly: the European Commission granted full marketing authorisation on 15 July 2026, making it the first oral GLP-1 medication approved for weight management in the EU.
But approved does not mean available. As of August 2026, no Irish pharmacy stocks the Wegovy pill, no Irish price has been announced, and Novo Nordisk has not confirmed an Irish launch date. So the question this post originally set out to answer - "when will I actually be able to get it?" - is still very much live.
This is the most comprehensive guide to the Wegovy pill for Irish patients. We cover what the pill is, what the clinical evidence says, the full regulatory timeline, now largely complete, the realistic Irish availability window, and what you should be doing in the meantime if you are clinically eligible for weight management treatment.
Update (August 2026): We have also published a dedicated article covering the EU approval in detail: The Wegovy Pill Is Now EU-Approved: What It Means for Irish Patients. If you want the short version focused on the approval news, start there. This page remains the full reference guide.
Treatment with any GLP-1 medication is subject to clinical assessment by an IMC-registered doctor. Not everyone is eligible, and a prescription is not guaranteed.
Keep me informed about availability of the Wegovy pill in Ireland
What Exactly Is the Wegovy Pill?
The Wegovy pill is an oral tablet form of semaglutide, the same active ingredient already available in the weekly Wegovy injection. Manufactured by Novo Nordisk, it contains 25mg of semaglutide and is taken once daily. Like the injection, it works as a GLP-1 receptor agonist, mimicking a natural gut hormone to reduce appetite, slow digestion, and help you feel fuller for longer.
It is important to distinguish this from Rybelsus, which is an oral semaglutide tablet already available in Ireland but licensed only for managing type 2 diabetes at doses up to 14mg. The Wegovy pill uses a significantly higher dose (25mg maintenance) specifically developed for weight management.
In plain terms: the pill is not a weaker or diluted version of the injection. Clinical trials have shown it delivers comparable results, without a needle.
What Does the Evidence Say?
The Wegovy pill has been rigorously studied through Novo Nordisk's Phase 3 OASIS clinical trial programme, which enrolled approximately 1,300 adults with obesity or overweight with one or more related health conditions. Direct trial link (OASIS 4).
The headline results from the OASIS 4 trial are striking: participants taking oral semaglutide 25mg achieved a mean weight loss of 13.6% at 64 weeks, compared to 2.2% in the placebo group. Among those who fully adhered to treatment, weight loss reached 16.6%. Crucially, approximately one in three participants achieved 20% or greater body weight loss, a result comparable to injectable Wegovy (STEP/OASIS comparator data).
Beyond weight loss, the trial also demonstrated improvements in blood pressure, blood glucose control, and cardiovascular risk markers. For those with prediabetes at baseline, more than 70% saw blood glucose normalise. The safety profile was consistent with what we already know from injectable semaglutide: the most common side effects being gastrointestinal (nausea, constipation, diarrhoea), which typically ease over time.
Eligibility for any weight loss medication depends on your individual health profile. A doctor must assess your suitability before prescribing. Start your free assessment here.
Wegovy Injection vs Wegovy Pill: How They Compare
Frequency
Injection: once weekly subcutaneous injection
Pill: once daily oral tablet
Maintenance dose
Injection: 2.4mg weekly
Pill: 25mg daily
Expected weight loss
Injection: ~14.9% average. Pill: ~13.6-16.6%.
Availability in Ireland
Injection: available now on private prescription. Pill: EU-approved, but not yet on sale.
Administration notes
Injection: more predictable absorption. Pill: fasting, 30 minutes before food.
Where Does the World Stand Right Now?
This is the section that has changed most significantly since we first published this guide in April 2026. Here is the current picture as of August 2026.
United States: The FDA approved the Wegovy pill on 22 December 2025, and Novo Nordisk launched it commercially in early January 2026. Within four months, more than one million Americans had started using the tablet. The US remains the most established market for the oral formulation.
European Union: On 21 May 2026, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorisation for oral semaglutide 25mg for weight management. The European Commission followed with formal approval on 15 July 2026. This means the Wegovy pill is now legally authorised across all EU member states, including Ireland.
United Kingdom: The UK's MHRA granted a separate approval on 11 June 2026, and the tablet launched in the UK on a private prescription basis shortly afterwards. NHS access is still under review.
UAE and Bahrain: Both countries have also approved the Wegovy pill, making a total of five regulatory approvals worldwide.
What about Ireland specifically?
This is where the distinction between "approved" and "available" becomes important. The EU marketing authorisation means the Wegovy pill is legally licensed for use in Ireland. A doctor could, in principle, prescribe it. But in practice, the medication is not yet being sold here. Novo Nordisk must allocate manufacturing supply, produce Irish-labelled packs, stock wholesalers, and set Irish pricing before any pharmacy can dispense it.
Novo Nordisk has said it is "committed to launching Wegovy pill in more countries in the second half of 2026," but has not specifically named Ireland or confirmed a date. No Irish pharmacy has published a price.
Ireland connection: In a significant vote of confidence in Irish manufacturing, Novo Nordisk announced a EUR 432 million investment to upgrade its Athlone facility specifically to manufacture the oral Wegovy pill for markets outside the US. The expansion is expected to come online gradually from end 2027 through 2028, meaning Ireland will play a direct role in supplying this medication to Europe.
Anyone claiming to sell the Wegovy pill in Ireland right now is selling something that is either unlicensed or not what it claims to be. Please avoid unregulated online sources.
The Ireland Timeline: Where We Are Now
When we first published this guide, most of the milestones below were still in the future. As of August 2026, the regulatory pathway is largely complete. What remains is the commercial launch and, separately, any HSE reimbursement decision.
Late 2025 to 15 July 2026: regulatory pathway completed
Novo Nordisk submitted oral semaglutide 25mg to the EMA, the FDA approved the Wegovy pill on 22 December 2025, the US launched it in January 2026, CHMP issued its positive opinion on 21 May 2026, the UK approved and privately launched it on 11 June 2026, and the European Commission granted full EU marketing authorisation on 15 July 2026.
Late 2026 to early 2027: Irish launch
Pharmacy stocking, pricing, and prescribing to eligible patients, awaiting Novo Nordisk launch.
TBD: HSE reimbursement decision via NCPE review
Private prescription access is likely to come first. The reimbursement process has not yet begun for the pill.
For context on how long these final steps can take: Novo Nordisk applied for HSE reimbursement for the Wegovy injection on 19 March 2025. More than sixteen months later, that process is still ongoing. The reimbursement pathway for the pill has not even begun. Private prescription access will almost certainly come first, as it did with the injection and with Mounjaro.
Who Will Be Eligible for the Wegovy Pill?
Based on the clinical trial criteria and the now-confirmed EU approved indication, the Wegovy pill is designed for adults who meet one of the following thresholds:
- BMI of 30 or above: the standard clinical threshold for obesity where medical intervention is recommended alongside lifestyle changes.
- BMI of 27-29.9: provided you have at least one weight-related health condition, such as high blood pressure, type 2 diabetes or prediabetes, high cholesterol, or cardiovascular disease.
In both cases, the pill is approved as an adjunct to a reduced-calorie diet and increased physical activity, not as a standalone treatment. This mirrors the indication for the injectable version.
One practical consideration worth flagging: the pill must be taken on an empty stomach in the morning (after fasting for at least eight hours), with up to 120ml of plain water, followed by a 30-minute wait before eating, drinking anything else, or taking other oral medications. This is a meaningful daily routine requirement that clinicians will discuss with patients, and it is stricter than most people expect.
These are general eligibility criteria. Whether you personally qualify depends on a full clinical assessment. At Bua Health, our clinical partners assess every patient individually. Start your free 2-minute assessment.
Should You Wait for the Pill?
This is still the question we hear most often at Bua Health, and the honest answer has not changed: for most people, probably not.
When we first published this guide, the pill was still awaiting EU approval and the realistic timeline was 12 to 18 months out. Today, EU approval is done. But Irish patients still cannot walk into a pharmacy and collect it. Based on the timeline for similar products, a realistic window for Irish availability is late 2026 at the earliest, more likely early 2027. And even then, private prescription access will come first, with any HSE reimbursement following at a pace that, based on experience, could take years.
Meanwhile, injectable Wegovy is available in Ireland right now, and has been since March 2025. So is Mounjaro. The evidence behind both is extensive, and for patients who are clinically eligible, delaying treatment when an equally effective option exists today is rarely in their best interest, either medically or practically.
Here is how we would think about it
If needle anxiety is the only thing stopping you: that is completely understandable, and it is worth knowing that the pill is now much closer than it was. But it is also worth a conversation with one of our clinicians about modern injection pens. Almost every patient who was anxious about injections tells us the experience was far easier than expected. The Wegovy and Mounjaro pens are pre-filled and designed to be straightforward, and our care team walks you through the first one.
If you have been waiting to start treatment at all: every month of delay is a month without the metabolic and cardiovascular benefits these medications provide. The clinical evidence is clear that earlier intervention produces better long-term outcomes. If you are eligible, starting now with the injection and switching to the pill later (if you prefer) is likely the best approach for your health.
If you are already on injectable Wegovy or Mounjaro: there is no clinical reason to switch to the pill when it becomes available unless you and your doctor decide that the oral form suits your lifestyle better. The injection and pill deliver comparable results.
At Bua Health, our clinical partners stay up to date with regulatory developments and will be ready to assess patients for the Wegovy pill as soon as it becomes available in Ireland. If you are already a Bua patient, we will let you know when it launches.
Ready to get started? You do not need to wait for the pill. Effective, medically supervised weight management is available in Ireland today. Start your free 2-minute assessment.
Ready to Get Started with Bua?
With Bua, you are supported by a specialist, doctor-led weight management service from day one. Here is how the process works:
1. Complete a 2-minute online assessment with your BMI, medical history, medications, and key health details.
2. Our clinical partners review your submission quickly and invite eligible patients to a remote GP consultation.
3. Start ongoing support from your care team, including monthly clinical check-ins, unlimited GP support, and dietitian guidance.
The Bua programme costs €50/month. Medication is dispensed through our partner pharmacy network, and you may be able to claim tax relief on your treatment costs.
Treatment is subject to clinical assessment by an IMC-registered doctor. Not everyone is eligible, and a prescription is not guaranteed.
Frequently Asked Questions
Related Reading
- Wegovy pill EU approved: what it means for Irish patients
- Do I Qualify for Wegovy in Ireland? BMI Criteria, Costs and Eligibility Explained (2026)
- Wegovy vs Mounjaro in Ireland: Which Weight Loss Injection Is Right for You?
Sources & References
- Novo Nordisk (December 2025). Wegovy pill approved in the US as first oral GLP-1 for weight management.
- European Medicines Agency (22 May 2026). CHMP positive opinion: Wegovy variation for oral tablets.
- Novo Nordisk / GlobeNewswire (15 July 2026). European Commission approval of Wegovy pill as first oral GLP-1 for weight management in the EU. 15 July 2026.
- Irish Medical Times (March 2025). Weight loss drug Wegovy now available in Ireland.
- Fierce Pharma (March 2026). Novo plugs $500M into Ireland plant to produce Wegovy pill for markets outside US.
- Applied Clinical Trials (December 2025). FDA Approves Oral Wegovy Following Positive Phase III OASIS 4 Trial Results.
- AJMC (December 2025). FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss.
- Wharton S, et al. Oral Semaglutide at a Dose of 25mg in Adults with Overweight or Obesity (OASIS 4). New England Journal of Medicine. 2025;393(11):1077-1087.
Related Blogs
Who Qualifies for Mounjaro in Ireland?
An overview of the clinical criteria, safety checks, and medical assessment process doctors use to decide who is eligible for Mounjaro® (tirzepatide) in Ireland.
Read
What weight loss injections are available in Ireland?
A clear breakdown of the three main medical treatments for weight management in Ireland in 2025 and 2026
Read
Who can't take Mounjaro? Understanding the contraindications
A comprehensive guide to the absolute contraindications and other cautions that determine who cannot safely take Mounjaro® (tirzepatide) in Ireland.
ReadWho Qualifies for Mounjaro in Ireland?
An overview of the clinical criteria, safety checks, and medical assessment process doctors use to decide who is eligible for Mounjaro® (tirzepatide) in Ireland.
What weight loss injections are available in Ireland?
A clear breakdown of the three main medical treatments for weight management in Ireland in 2025 and 2026
Who can't take Mounjaro? Understanding the contraindications
A comprehensive guide to the absolute contraindications and other cautions that determine who cannot safely take Mounjaro® (tirzepatide) in Ireland.